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ilated cardiomyopathy (DCM) is often a genetic disease. DCM is also the more genetically diverse of the common cardiomyopathies that include hypertrophic cardiomyopathy, left ventricular noncompaction, and arrhythmogenic right ventricular cardiomyopathy. 1 There are currently >70 genes with mutations linked to DCM. 2 These mutations are found in genes that contribute to diverse functions including sarcomere machinery, the nuclear membrane, calcium handling, metabolic processes, ion channels, and cytoskeletal networks. Phenotypically, DCM is characterized by ventricular dilation and impaired cardiac function that can lead to heart failure.
Genetic testing for cardiomyopathies relies on gene panels, focusing on exons and the immediate intronic regions. 3 The sensitivity of clinical gene panel testing is 40% to 50% in DCM, suggesting the involvement of additional genes or even combinations of genes. The most commonly mutated gene in DCM is TTN, which encodes the giant protein titin that confers elasticity and stability to the sarcomere. Heterozygous TTN truncations are found in ≈20% of DCM 4 and ≈1% of the general population. Mutations in MYBPC3, which also encode a major component of the sarcomere, more commonly lead to hypertrophic cardiomyopathy. 5, 6 MYBPC3 encodes cardiac MyBP-C (myosin-binding protein-C), a protein that binds directly to myosincontaining thick filaments. The majority of gene mutations in DCM and hypertrophic cardiomyopathy are autosomal dominant heterozygous variants. Cardiac MyBP-C is a cardiac-specific protein composed of repeating immunoglobulin (Ig) and fibronectin III (FnIII) domains. Many MYBPC3 mutations are heterozygous truncating genetic variants. 6 Individuals with heterozygous MYBPC3 truncating mutations have been described with a range of severity of hypertrophic cardiomyopathy and variable penetrance. 7, 8 Truncating MYBPC3 mutations may act through haploinsufficiency and improper actomyosin crossbridge regulation, 9 although other mechanisms may occur. 10, 11 Truncating mutations remove the myosinbinding, carboxyl terminus of cMyBP-C, resulting in improper myofilament incorporation and degradation of the truncated protein. 8 In this work, we describe the application of wholegenome sequencing (WGS) to a family with DCM and associated cardiac conduction system disease. WGS was used to determine genetic variation because WGS applies more even sequencing coverage across exons and, importantly, samples more exons, including those that may not be present on whole-exome sequencing arrays. We identified a premature stop codon (stopgained) in MYBPHL. We found that MyBP-HL (myosinbinding protein-H like) is related to other well-studied myosin-binding proteins, and that it is a cardiac myofilament protein enriched in the atria and expressed in the ventricular conduction system. Because MYBPHL truncating variants are found at a higher than expected population frequency for a rare disorder, we assessed both heterozygous and homozygous loss of Mybphl in the mouse. We found that disruption of Mybphl in the mouse leads to cardiomyopathy and associated arrhythmias, demonstrating the importance of MyBP-HL in normal cardiac function.
METHODS

Study Subjects
Peripheral blood was collected for WGS and confirmation Sanger sequencing. The study was approved by both the University of Chicago and Northwestern University Institutional Review Boards. Genetic counseling was provided.
Whole-Genome Sequencing
Blood was collected from subjects and genomic DNA was extracted. Massively parallel sequencing was performed by Illumina on a HiSeq2000 or X-Ten to generate >30× coverage WGS data. Paired end reads were mapped to hg19
Clinical Perspective
What Is New?
• We identified a low-frequency premature stop codon in the MYBPHL gene.
• MYBPHL encodes MyBP-HL (myosin-binding protein H-like) and shares homology with other myosin-binding proteins.
• MYBPHL is expressed highly in atria and at a low level in the ventricle, and is found in a punctate ventricular pattern suggestive of the conduction system. • MyBP-HL protein interacts with the cardiac myofilament.
• We characterized mice with a heterozygous or homozygous deletion in Mybphl and found dilated cardiomyopathy and cardiac conduction system disease, recapitulating the clinical phenotype.
What Are the Clinical Implications?
• Heterozygous truncating mutations in the TTN and MYBPC3 genes cause inherited forms of cardiomyopathy with variable expressivity and penetrance.
• TTN and MYBPC3 encode the myofilament proteins titin and myosin-binding protein C, respectively. • We have now identified a novel myofilament component, MyBP-HL, and described mice with disruption in the Mybphl gene as having cardiomyopathy and arrhythmias. • MYBPHL's unusual expression pattern, atria and punctate in the ventricle, suggests a novel mechanism for ventricular dysfunction.
ORIGINAL RESEARCH ARTICLE and variants were called using MegaSeq, 12 which uses the Burrows-Wheeler aligner, Genome Analysis Tool Kit, and Haplotype Caller for variant identification. SnpEff was used to classify variants according to predicted protein alteration into classes that include HIGH, MODERATE, MODIFIER, and LOW effect variants.
13 MODERATE (missense) variants were scored using Polyphen2 and GERP. 14, 15 Left ventricular and atrial appendage expression data from the GTEx database were used to prioritize genes expressed in the heart. 16 Variants were further annotated with data from ClinVar, 17 and the MalaCards database using cardiomyopathy specific keywords. 18 All variants were annotated with both global and continental Exome Aggregation Consortium (ExAC) frequencies, 19 and sorted based on rare frequency in the global ExAC population (<0.002).
IACUC Statement
All experiments were performed in accordance with protocols reviewed and approved by the IACUC at Northwestern University.
Mybphl Targeted Deletion in Mice
A mouse line with a targeted deletion of Mybphl exons 2 to 6 was created by the National Institutes of Health Knock-Out Mouse Project 20 in association with the Welcome Sanger Trust and obtained from the European Mutant Mouse Archive. The targeted allele contained a LacZ reporter, a LoxP site, a neo cassette, a second FRT site, and a second LoxP site between exons 1 and 2. A third LoxP site was located between exons 6 and 7. This allele was bred to the Ella deleter mouse, causing recombination and resulting in the tm1b allele configuration, with exon 1 splicing into the LacZ reporter. These mice were archived on a C57/Bl6(N) background and rederived from frozen sperm at Northwestern University on a C57/Bl6(J) line by the Transgenic and Targeted Mutagenesis Laboratory at Northwestern.
Echocardiography
Echocardiography was performed using a Vevo2100 echocardiography platform with a 550-MHz solid-state probe (FujiFilm). Mice were imaged on a heated table with surface electrocardiogram (ECG) recordings. Isoflurane anesthesia was used at 1% during acquisition; if the heart rate fell to <450 beats per minute, the session was reperformed. Chamber dimensions were measured by short-axis M-mode echocardiography.
Mouse Cardiac Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) was performed on a 9.4T Bruker Biospec MRI system with a 30-cm bore, a 12-cm gradient insert, and an Autopac automated sample positioning system (Bruker Biospin Inc.). Atria were imaged by using a prospectively triggered flow compensated cine FLASH sequence with repetition time/echo time/α=10 ms/2.4 ms/15°, matrix size 192×192, field of view 3 cm×3 cm, slice thickness 1 mm, and 12 frames per cardiac cycle. Analysis was performed on the coronal images using Segment version 2.0 R5450.
21,22
Antibodies, Immunofluorescence Microscopy, and Immunoblotting Cardiomyocytes were isolated from 1.5-day-old neonatal mice using the Pierce Primary Cardiomyocyte Isolation Kit (Thermo 88281). Cells were transfected using Lipofectamine 3000 (Life Technologies L3000008) according to the manufacturer's specifications using endo-free pCMV6 plasmids encoding mouse Mybphl with and without the R255X variant with amino-terminal Myc-DDK tags. Cells were fixed in 4% paraformaldehyde for 10 minutes, permeabilized in 0.25% Triton X-100 in phosphate-buffered saline for 20 minutes, and blocked using 20% fetal bovine serum, 0.1% Triton X-100 in phosphate-buffered saline for 30 minutes. Cells were incubated with Anti-Myc antibody (Millipore 05-724) and Phalloidin 488 (Molecular Probes A12379). Images were taken using a Zeiss Axio Observer epifluorescence microscope with an Apotome-2.
Atria and ventricle tissue were homogenized in urea buffer (50 mmol/L Tris HCl, pH 7.5, 4 mol/L urea, 1 mol/L thiourea, 0.4% 3-[{3-cholamidopropyl}dimethylammonio]-1-propanesulfonate hydrate, 20 mmol/L spermine, 20 mmol/L dithiothreitol) using silica beads and a homogenizer (BioSpec) for total protein. Myofilament fractions were isolated by homogenizing tissue in F60 buffer (60 mmol/L KCl, 30 mmol/L imidazole, 2 mmol/L MgCl 2 ) for total protein, then centrifuging at 12 000 relative centrifugal force at 4°C to separate the soluble protein fraction in the supernatant. The myofilament fraction was washed by homogenizing 3 times in F60 with 1% Triton X-100 and 12 000 relative centrifugal force centrifugations and finally solubilized in urea buffer. 23 Antibodies used for immunoblotting were cMyBP-C E-7 (Santa Cruz sc137180, lot K3011), MyBP-HL N-16 (SC sc248025, lot G2412), and Annexin 6 (AbCam ab31026).
Quantitative Polymerase Chain Reaction
Gene expression was assessed by quantitative polymerase chain reaction using SybrGreen chemistry measured by a CFX96 thermocycler (BioRad). Primers were designed against exon 8 and the 3ʹ untranslated region in exon 9 of Mybphl (forward 5ʹ TCACATCCACAAGGCAGATATT 3ʹ, reverse 5ʹ TATAGCCAGGAGTGGAGGTATG 3ʹ, efficiency 104.3%) and primers designed against Mybph (forward 5ʹ TCACATCCACAA GGCAGATATT3ʹ, reverse 5ʹ TATAGCCAGGAGTGGAGGTATG 3ʹ, efficiency 103.5%). Expression was normalized to Gapdh (forward 5ʹ TTGTGATGGGTGTGAACCACGA 3ʹ, reverse 5ʹ AGCCCTTCCACAATGCCAAAGT3ʹ, efficiency 102.7%). Expression was calculated by using an efficiency-corrected ΔΔCq equation.
Detailed methods for mouse cardiac MRI, histology, continuous telemetry, and induced pluripotent stem cell generation and differentiation are found in the Methods in the online-only Data Supplement.
Statistical Methods
Statistical evaluation was performed using GraphPad Prism7. Significance was set a priori at P<0.05. Two-way ANOVA was performed with a Bonferroni multiple comparison test for experiments for human RNA-seq data, mouse echocardiography, and mouse heart rates after isoproterenol. One-way ANOVA was performed with the Tukey multiple comparison test for experiments using mouse reverse transcription polymerase chain reaction, protein quantitation, and atrial weight to body weight. Assumed equality of variance for ANOVA calculations were tested by a Bartlett test. An unpaired t test was performed to compare right atrial volumes by MRI. Statistical tests are indicated for each data set in the legend.
RESULTS
WGS Identifies a Premature Stop in MYBPHL Associated With Conduction System Abnormalities and DCM
A family with a clinical history of conduction system abnormalities and DCM was evaluated ( Figure 1 ). The proband (II-1) had congenital complete heart block with a pacemaker implanted at 12 years of age, followed by progressive DCM and heart failure. The proband died of progressive heart failure and arrhythmia in his fourth decade. Medical records from the year before death show severe left ventricular systolic dysfunction with a left ventricular ejection fraction <25% and impaired conduction system function. Four-chamber echocardiography imaging of his mother (I-2) showed marked atrial dilation ( Figure 1B) , DCM, and reduced systolic function. ECG recordings from the proband showed profound sinus and atrioventricular node dysfunction in the absence of pacing ( Figure 1C , left). Premature ventricular contractions were also present. ECGs from the proband's mother (I-2) showed atrial flutter, premature ventricular contractions, and junctional beats; she required atrioventricular node ablation for management ( Figure 1C , middle). Siblings II-2 and II-3 also had pacemaker implantation for complete A, WGS on the proband (II-1) and parents (I-1, I-2) identified the MYBPHL R255X variant that was found in multiple family members. B, Four-chamber echocardiogram of I-2 shows enlarged right and left atria (LA, RA). C, Abnormal heart rhythms in multiple family members. Electrocardiogram (ECG) recordings from the proband's pacemaker test months before death showing paced rhythm (top, lead 1). In the middle tracing with the pacemaker off, underlying sinus and atrioventricular node dysfunction was evident, as were PVCs (arrow heads). The bottom tracing highlights a paced rhythm and revealed PVCs (arrow head). The center tracings show ECG recordings from the affected parent (I-2) that demonstrate atrial flutter (asterisks) and a PVC (middle tracing). The bottom tracing shows pacing after atrioventricular (AV) node ablation with persistent atrial flutter (asterisks). The right-hand recordings show ECG tracing from II-3 with a PVC (arrow head) and coarse atrial fibrillation (asterisks). AVN indicates atrioventricular node; DCM, dilated cardiomyopathy; HF, heart failure; PVC, premature ventricular contraction; SIDS, sudden infant death syndrome; and WGS, whole-genome sequencing.
heart block, both at 11 years of age, with DCM developing later (Table) . ECG recordings from sibling II-3 also show atrial flutter and junctional ventricular arrhythmia ( Figure 1C , right). The expanded pedigree of the mother (I-2) indicated other family members with DCM and arrhythmias ( Figure I in the online-only Data Supplement). The clinical findings are summarized in the Table. Clinical genetic testing with a broad cardiomyopathy gene panel was unrevealing in this family. To identify the genetic etiology, WGS was performed on the proband (II-1) and parents (I-1, I-2). Variants were sorted by frequency (ExAC <0.002), and variant effects were determined by using snpEff focusing on HIGH and MODERATE effect variants. HIGH effect variants disrupt protein length and include stop/start loss/gain, frameshifts, and splice site variants. MODERATE effect variants include missense and in-frame insertion/deletions. No mutations were seen in genes previously linked to DCM, so we evaluated the remainder of the genome for HIGH and MODERATE effect variants focusing on genes highly expressed in the heart. We identified a HIGH effect variant in MYBPHL (1:109838960 G>A) that substitutes a stop codon for the arginine at residue 255 (of 354) (Figure 2A ). Sanger sequencing confirmed this presence of MYBPHL R255X in multiple affected family members ( Figure 2 ). We identified MYBPHL R255X in 1 of 198 subjects with cardiomyopathy examined using WGS. Although the MYBPHL R255X variant is rare in the overall population, it is found at a higher than expected frequency based on population estimates and genetic heterogeneity of DCM (Table I in the online-only Data Supplement). Because of the observed population frequency in ExAC, we queried 900 genomes sequenced from the NUGene database, representing individuals who receive care at Northwestern Medicine. We identified MYBPHL R255X variant in 1 individual (1:1800 alleles). At age 30, this variant carrier had 2 echocardiograms with a left ventricular internal dimension in diastole that exceeded normal values (3.0 and 2.8 cm/m 2 , with normal being 2.1-2.7 cm/m 2 ). The left ventricular ejection fraction was normal in these studies, but the enlarged left ventricular dimension is consistent with early-phase DCM. Based on these findings, we investigated both cells and mice with MYBPHL truncations.
Because premature stop codons may be subject to nonsense-mediated decay, we assessed allele-specific expression of MYBPHL, taking advantage of polymorphisms that distinguish the mutant and normal alleles ( Figure 2B ). We generated cardiomyocytes from induced pluripotent stem cells from family members I-1 (unaffected father) and I-2 (affected mother) (Figure 2C ). Direct sequencing of MYBPHL complementary DNA from individual I-2 identified expression from only the normal G-containing allele ( Figure 2D and 2E), and there was no detectable signal from the mutant MYBPHL allele ( Figure 2E , lower). We also evaluated a second benign synonymous single-nucleotide polymorphism (1:109839482 C>T) in individual I-2, where the A allele is found on the normal MYBPHL allele ( Figure 2F ). Direct sequencing of complementary DNA confirmed expression only from the normal allele ( Figure 2G ) with no detectable expression from the R255X allele. These findings demonstrate that MYBPHL R255X is subject to nonsense-mediated decay. Nonsense-mediated decay has been described as contributing to MYBPC3 truncations. 
MYBPHL Expression Is Enriched in Human and Mouse Atria
There are 2 related genes, MYBPHL and MYBPH, with both genes residing on human chromosome 1 (Figure 3) , and on mouse chromosomes 3 and 1, respectively. Human RNA-seq data demonstrated that MYBPHL is enriched in the heart, whereas MYBPH is enriched in skeletal muscle. 16, 25 Moreover, MYBPHL is much more highly expressed in left atria than in left ventricles (Figure 3B) . These data are consistent with MYBPH as the primary H protein in skeletal muscle, and MYBPHL as the H protein in the heart, with higher expression in atria. RNA-seq data from mouse tissues demonstrated a similar pattern, with significantly higher Mybphl expression in the right and left ventricles than in Mybph and negligible expression in skeletal muscle. As in humans, mouse Mybph was highly expressed in skeletal muscle ( Figure 3C ). Expression levels of Mybphl and Mybph were confirmed by quantitative polymerase chain reaction using mouse atria, left and right ventricles, and skeletal muscle. These data confirmed Mybphl expression in the ventricles, with >10 000-fold enrichment in the atria. Mybph was detected in small amounts in the ventricles, but was increased >100-fold in skeletal muscle ( Figure 3D ).
MYBPHL Interacts With the Myofilament
We compared MYBPHL with the better-studied myosin-binding proteins. Protein alignment of cMyBP-C, MyBP-H, and MyBP-HL shows homology among these 3 myosin-binding proteins, with H and HL having the highest relatedness to each other (82% conserved amino acids) and HL having 65% similarity to cMyBP-C (Figure 4A and 4B) . The 3 carboxy-terminal domains, seen I-2 has the G>A stop variant in exon 6, and a synonymous SNP on the opposite allele in exon 5. C, Representative phalloidinstained image of iPSC-derived cardiomyocytes generated from family members I-1 and I-2. D, Sanger sequencing of iPSCcardiomyocyte genomic DNA confirms the presence of reference sequence in I-1 and the 1:109838960G>A variant in I-2. E, Direct sequencing of RT-PCR-generated complementary DNA (cDNA) from iPSC-cardiomyocytes from I-1 and I-2 shows expression of only the normal G allele (expressed as a C) in both I-1 and I-2. This is consistent with no detectable expression from the premature stop allele in I-2. F, Direct sequencing of genomic DNA from iPSC-cardiomyocytes from I-1 and I-2 showed the presence of a benign synonymous C>T SNP in exon 5 of I-2. This variant is found on the opposite allele from R255X. G, Direct sequencing of RT-PCR product generated from iPSC-cardiomyocyte cDNA showed that I-2 only expressed the allele with the C>T SNP, consistent with nonsense mediated decay of the mutant allele. bp indicates base pairs; iPSC, induced pluripotent stem cell; RT-PCR, reverse transcription polymerase chain reaction; and SNP, single-nucleotide polymorphism.
as Ig-Fn-Ig domains in Figure 4A , are shared among these myosin-binding proteins. In studies of cMyBP-C and H protein, these domains are necessary for proper sarcomere incorporation by direct binding to the myosin thick filament. [26] [27] [28] To determine whether MyBP-HL interacts with the myofilament, wild-type mouse atria, right and left ventricles, and ventricular septum were assessed for total, myofilament, and soluble protein fractions ( Figure 4C ). Cardiac MyBP-C was used as a myofilament positive control, because it was observed in the total and myofilament fractions from each chamber as expected. 23 The membrane-associated protein annexin A6 was used as a positive control for the soluble fraction. 29 MyBP-HL protein was observed in the total and myofilament fractions of atria, reflecting its high expression in atrial tissue and its association with myofilaments.
To visualize the subcellular localization of MyBP-HL, a Myc-DDK epitope tag was added to the amino terminus, and full-length mouse Mybphl complementary DNA and truncated (R255X) constructs were introduced into neonatal mouse cardiomyocytes. Full-length MyBP-HL was observed to localize to the myofilament, with distinct doublets flanked by phalloidin-stained actin M lines ( Figure 4D , red and green arrows). The truncated MyBP-HL protein showed diffuse staining at the periphery of cells without any discernable incorporation into the myofilament. This indicates that the premature stop codon disrupts normal localization, similar to how truncating MYBPC3 gene mutations disrupts cMyBP-C. These data indicate that MyBP-HL is natively myofilament-associated in the atria, and, when expressed in neonatal ventricular cardiomyocytes, the protein is able to incorporate into the myofilament in a pattern similar to cMyBP-C C-zone doublets ( Figure II in the onlineonly Data Supplement).
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Mybphl Is Expressed in Atria and in Puncta Throughout the Ventricles
To study the physiological role of MyBP-HL, we obtained an Mybphl allele generated by the Knock-Out Mouse Project. 20, [32] [33] [34] [35] This allele removes Mybphl exons 2 through 6, which includes the majority of the protein-coding region and inserts a LacZ reporter 3ʹ of exon 1 ( Figure 5A ). Mice were derived onto a C57Bl6/J background; heterozygous and homozygous mice were produced in normal Mendelian ratios, indicating no lethality on this background (Table II in homogenates from homozygous mice by immunoblotting ( Figure 5C ), confirming that the deletion strategy generated a null allele.
The LacZ reporter was used to examine the expression of Mybphl in the mouse heart. Consistent with the RNAseq data, Mybphl-LacZ was highly expressed in atria. We also identified LacZ-positive puncta throughout the ventricle ( Figure 5D ). The nature of these ventricular puncta was studied by using serial 10-µm sections spanning an ≈700-µm-thick anterior region of myocardium containing right ventricular free wall, septum, and left ventricular free wall ( Figure IV in the online-only Data Supplement). β-galactosidase puncta were seen in Mybphl heterozygous hearts but not in controls. These puncta were mapped on a representative section, with 1 dot representing either a single β-galactosidase-positive focus, or 
Loss of Mybphl Results in Ventricular Dysfunction and Atrial Enlargement
We evaluated the consequences of the loss of Mybphl on cardiac function in 12-week-old mice by using echocardiography analysis. M-mode-derived data revealed significantly larger left ventricle internal diameter during peak diastolic filling in both Mybphl heterozygous (Het) and null mice (male: wild-type [WT]=3.77±0.09 mm, Het=4.13±0.06 mm, null=3.95±0.11 mm; female: WT=3.47±0.15 mm, Het=3.71±0.04 mm, null=3.80± 0.06 mm) ( Figure 6A and 6B), consistent with moderate dilation of the ventricle. Fractional shortening was reduced in both heterozygous and homozygous mice (male: WT=31.1±1.7%, Het=20.6±1.2%, null=19.7±1.18%; female: WT=37.8±3.8%, Het=23.4± 1.7%, null=18.7±1.2%) ( Figure 6A and 6B) .
Heart mass to body mass ratios were not significantly different among the groups ( Figure 6C) . However, the ratio of atrial mass normalized to total heart mass was significantly increased in both heterozygous and homozygous groups (WT=0.058±0.004, Het=0.074±0.003, null=0.078±0.005) ( Figure 6C ). We used cardiac MRI on WT and Mybphl null mice to examine atrial morphology in vivo ( Figure 6D ). The atria were imaged at peak ventricular systole to capture peak atrial filling. Right atrium volume was significantly increased in Mybphl null animals in comparison with WT (WT=20.9±0.2 µL, Mybphl null=33.7±1.4 µL) ( Figure 6E ). Therefore, loss of Mybphl in the mouse impaired left ventricular function and caused atrial enlargement.
Mybphl Deletion Increases Susceptibility to Arrhythmias
We performed conscious ambulatory ECG recordings to assess the arrhythmogenic risk in Mybphl heterozygous and homozygous mice. Average heart rate and QRS duration did not differ among the groups under normal conditions. However, after administration of isoproterenol, the Mybphl null mice showed a significant increase in QRS duration in comparison with WT mice treated with isoproterenol (baseline: WT=13.3±0.6 ms, Het=13.2±0.4 ms, null=13.2±0.4 ms; isoproterenol: WT=12.8±0.2 ms, Het=13.9±0.8 ms, null=15.2±0.4 ms) ( Figure 7A ). Thus, ventricular conduction was significantly slowed in Mybphl null hearts following adrenergic stimulation, consistent with a role for the low-level expression of MyBP-HL seen in a punctate pattern in the ventricle.
To assess if loss or reduction of MyBP-HL increased the likelihood of arrhythmia, ECG traces from these mice were analyzed blinded to genotype. Following isoproterenol injection, the total number of premature ventricular contractions normalized to time was higher in the heterozygous group, whereas both heterozygous and null mice showed an increased occurrence of nonconducted ventricular beats ( Figure 7B and 7C, Figure  VI in the online-only Data Supplement). In addition to the frequently observed premature ventricular contractions and missed QRS events, heterozygous and null mice also displayed instances of sinus arrest, gradual inversion of P waves indicating possible ectopic atrial rhythms, and bigeminy resulting in increased P-P and R-R variability ( Figure VI in the online-only Data Supplement, arrows). None of these specific events was observed in WT recordings at baseline or following isoproterenol administration.
Under baseline conditions and following adrenergic stimulation, heterozygous and homozygous mice exhibited notable bigeminy and irregular rhythms. These irregularities were visualized by the use of Poincaré plots, plotting the R-R interval of 1 beat with the R-R interval of the following beat as (x,y) pairs ( Figure 7D) . 36 Representative Poincaré plots from individual animals with and without isoproterenol treatment showed increased variability in the heterozygous and null animals (baseline ≈60 000 beats per plot, isoproterenol ≈30 000 beats per plot) (Figure 7D) . Heart rate variability was also visualized by plotting the ratio of 1 R-R interval and the R-R interval of the following beat on a histogram ( Figure 7E) , with peaks at 2 and 3 corresponding with 1 or 2 nonconducted beats in sinus rhythm (arrows iii and iv), points below 1 corresponding to premature ventricular contractions (arrow i), and the wider distribution of the heterozygous and null ratios illustrating increased beat-to-beat variability (bar ii). These data indicate that Mybphl regulates conduction in the atria and ventricular conduction systems. In this report, we used WGS to identify a gene associated with cardiac conduction defects and DCM in humans. Mice deleted for Mybphl provide corroborating evidence that MyBP-HL has important roles for cardiac function in the mammalian heart. In the human population, MYBPHL R255X has a population frequency of 0.1% in the ExAC database (Table I in the online-only Data Supplement), a database that was assembled including individuals with a number of clinical disorders including cardiac phenotypes. It is notable that, although rare, 0.1% is higher than expected for a rare disorder. DCM itself is reported as occurring in 1 in 250 to 500 people (0.2%-0.4%). 37 Incomplete penetrance and variable expressivity are hallmarks of genetic cardiomyopathy, and this higher than expected frequency indicates that MYBPHL truncations may be insufficient on their own and instead act in concert with other stressors to express a cardiac phenotype. Additional studies documenting an enrichment of MYBPHL truncations in DCM populations are needed to develop statistical evidence for MYBPHL as a DCM gene.
TTN truncating variants (TTNtvs) are responsible for ≈20% of inherited DCM, yet TTNtvs are found in ≈1% to 3% of the general population. 4, 38 Although it appears that TTNtvs in cardiomyopathy enrich in the A band, the population prevalence of A-band TTNtvs is ≈0.19%, considerably higher than the incidence of DCM and consistent with reduced penetrance. 39 Despite this reduced penetrance, TTNtvs are a major genetic risk factor for developing DCM. Genetic and environmental effects are expected to influence the expression of pathogenic variants. Both cis-acting and trans-acting genetic modifiers likely contribute to disease manifestation. Thus, in humans, this truncating variant in MYBPHL may increase risk for developing arrhythmias and DCM.
The Major Myosin-Binding Proteins Share Conserved Myofilament-Binding Residues
Myosin-binding proteins C and H were originally described from skeletal muscle extractions. 40, 41 The structure of MyBP-C was described as a chain of immunoglobulin (Ig)-like and fibronectin type 3 (FnIII) domains that bind to myosin thick filaments and titin via 4 carboxy-terminal FnIII-Ig-FnIII-Ig domains. 42 These domains are recapitulated in MyBP-H and similarly bind myosin. 28 Despite a similar domain structure, electron microscopy of skeletal muscle has shown skeletal MyBP-C and -H to localize differently in the sarcomere, with C protein occupying 7 to 9 axial stripes within the A band of cardiac and skeletal muscle, and H protein occupying 1 stripe in the A band. 30 In addition to cardiac MyBP-C, the fast and slow MyBP-C proteins exhibit the same basic conserved domain structure. [43] [44] [45] [46] Specifically, all 3 C-type proteins share the carboxy-terminal myosin-binding residues, which bear resemblance to those found in MyBP-H and MyBP-HL. MyBP-HL lacks the extra FnIII domain at its amino terminus. The highly enriched skeletal and cardiac muscle expression pattern of MyBP-H and MyBP-HL suggests that these 2 genes should be viewed as skeletal and cardiac H protein, respectively. This classification is similar in part to the MyBP-C isoforms, with the exception of the skeletal MyBP-C isoforms that have split into 2 proteins in mammals. 46 MyBP-H was described as being expressed in the cardiac conduction system, specifically in Purkinje cells of the conduction system. 47 However, the methodologies may have been confounded by the existence of MyBP-HL. Given the high degree of similarity between these proteins, immunoreagents are likely to detect both proteins. A more recent study identified Mybph binding partners and subcellular localization in cardiac Purkinje cells, finding a protein similar in size to MyBP-HL on immunoblotting using a commercially available antibody that may detect both proteins (Abcam #ab55561). 48 Using a LacZ reporter in the Mybphl locus, we identified focal expression throughout the myocardium in a pattern consistent with Purkinje cell distribution. Moreover, the finding of both atrial and ventricular arrhythmias in Mybphl mutant mice provides a functional correlate. There are many cell types that comprise the conduction system, some with blurred boundaries with nonconduction system ventricular cardiomyocytes. The cardiac conduction system may express both Mybph and Mybphl; however, the low expression of Mybph in the heart suggests that this role may be more likely conferred by Mybphl. However, isoform-specific reagents are needed to confirm these findings.
Enriched Atrial Expression of Mybphl
We detected high expression of Mybphl in atria in both human and mouse with little ventricular expression. Yet deletion of Mybphl in mice leads to ventricular dysfunction, even in heterozygous mutant mice. The absence of ventricular hypertrophy and myofibrillar disarray in Mybphl null hearts stands in contrast to Mybpc3 null mouse models 26, 49, 50 and is consistent with low expression of MYBPHL in the ventricle. The data presented here support a model in which disruption of MYBPHL in the ventricle may disrupt the conduction system, which could lead to ventricular dysfunction. Alternatively, atrial dysfunction may predispose to ventricular dysfunction, which would be highly novel.
RNA-Seq evaluating gene expression in atrial cardiomyocytes and microdissected sinoatrial node cells showed Mybphl to be equally expressed in both cell types. 51 Furthermore, RNA-seq data from isolated cardiac Purkinje cells and working ventricular myocardium reported Mybphl expression as enriched in Purkinje cells (53.23±26 fragments per kilobase of exon per million fragments mapped in Purkinje cells versus 6.43±3.37 in ventricular cells). 52 These data, along with the observation of ventricular arrhythmias in Mybphl null mice and ventricular Mybphl-driven β-galactosidase puncta, support the hypothesis that Mybphl is expressed in specific and critical locations in the ventricular conduction system. The mechanism by which the loss of Mybphl elicits ventricular arrhythmias is unknown and could be attributable to structural and morphological changes leading to perturbations in conduction. Alternatively, MyBP-HL may be able to regulate intracellular signaling
